FRAX updates 2016

Current Opinion in Rheumatology

Volumn 28, Issue 4, 2016, Pages 433-441

  McCloskey, Eugene V ^a,b   Harvey, Nicholas C ^c   Johansson, Helena ^a   Kanis, John A ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

falls; FRAX; intervention thresholds; trabecular bone score; treat to target

Indexed keywords

ALGORITHM; BONE DENSITY; FALLING; FRACTURE; HUMAN; IMMIGRANT; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; TRABECULAR BONE; TREATMENT RESPONSE; ETHNOLOGY; HIP FRACTURES; MIGRANT; OSTEOPOROTIC FRACTURES; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES;

BONE DENSITY CONSERVATION AGENT;

ACCIDENTAL FALLS; ALGORITHMS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; EMIGRANTS AND IMMIGRANTS; HIP FRACTURES; HUMANS; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; RISK ASSESSMENT; RISK FACTORS;

EID: 84966430285     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000304     Document Type: Review

References (70)

1. Kanis JA; on behalf of the WHO Scientific Group. Assessment of osteoporosis at the primary health-care level. Technical Report. UK, Sheffield: WHO Collaborating Centre, University of Sheffield; 2008S
2. Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008; 19: 385-397; 18292978
3. Johansson H, Kanis JA, Oden A, et al. BMD, clinical risk factors and their combination for hip fracture prevention. Osteoporos Int 2009; 20: 1675-1682; 19291344
4. Compston J, Bowring C, Cooper A, et al. Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas 2013; 75: 392-396; 23810490
5. Cosman F, De Beur SJ, LeBoff MS, et al. Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int 2014; 25: 2359-2381; 25182228
6. Kanis JA, McCloskey EV, Johansson H, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2013; 24: 23-57; 23079689
7. Lekamwasam S, Adachi JD, Agnusdei D, et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 2012; 23: 2257-2276; 22434203
8. Kanis JA, Johansson H, Oden A, et al. Worldwide uptake of FRAX. Arch Osteoporos 2014; 9: 166; 24420978
9. Cauley JA, El-Hajj Fuleihan G, Arabi A, et al. Official Positions for FRAX(R) clinical regarding international differences from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(R). J Clin Densitom 2011; 14: 240-262; 21810532
10. Johansson H, Oden A, Lorentzon M, et al. Is the Swedish FRAX model appropriate for Swedish immigrants? Osteoporos Int 2015; 26: 2617-2622; 26018091
11. Kanis JA, Hans D, Cooper C, et al. Interpretation and use of FRAX in clinical practice. Osteoporos Int 2011; 22: 2395-2411; 21779818
12. Hans DB, Kanis JA, Baim S, et al. Joint Official Positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX((R)). Executive Summary of the 2010 Position Development Conference on Interpretation and use of FRAX(R) in clinical practice. J Clin Densitom 2011; 14: 171-180; 21810521
13. Kanis JA, Johansson H, Oden A, McCloskey EV. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 2011; 22: 809-816; 21229233
14. Johansson H, Kanis JA, Oden A, et al. Impact of femoral neck and lumbar spine BMD discordances on FRAX probabilities in women: a meta-analysis of international cohorts. Calcif Tissue Int 2014; 95: 428-435; 25187239
15. Leslie WD, Lix LM, Johansson H, et al. Spine-hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement. Osteoporos Int 2011; 22: 839-847; 20959961
16. Ammann P, Rizzoli R. Bone strength and its determinants. Osteoporos Int 2003; (14 Suppl 3: ): S13-S18; 12730800
17. Yang L, Peel N, Clowes JA, et al. Use of DXA-based structural engineering models of the proximal femur to discriminate hip fracture. J Bone Miner Res 2009; 24: 33-42; 18767924
18. Faulkner KG, Cummings SR, Black D, et al. Simple measurement of femoral geometry predicts hip fracture: the study of osteoporotic fractures. J Bone Miner Res 1993; 8: 1211-1217
19. Keaveny TM, Kopperdahl D, Melton L, et al. Age-dependence of femoral strength in white women and men. J Bone Miner Res 2009; 25: 994-1001
20. Gluer CC. Quantitative ultrasound: it is time to focus research efforts. Bone 2007; 40: 9-13; 16949359
21. Guerri-Fernandez RC, Nogues X, Quesada Gomez JM, et al. Microindentation for in vivo measurement of bone tissue material properties in atypical femoral fracture patients and controls. J Bone Miner Res 2013; 28: 162-168; 22887720
22. Randall C, Bridges D, Guerri R, et al. Applications of a new handheld reference point indentation instrument measuring bone material strength. J Med Dev 2013; 7: 410051-410056; 24115973
23. Silva BC, Leslie WD, Resch H, et al. Trabecular bone score: a noninvasive analytical method based upon the DXA image. J Bone Miner Res 2014; 29: 518-530; 24443324
24. Harvey NC, Gluer CC, Binkley N, et al. Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice. Bone 2015; 78: 216-224; 259886600
25. Leslie WD, Aubry-Rozier B, Lamy O, et al. TBS (trabecular bone score) and diabetes-related fracture risk. J Clin Endocrinol Metab 2013; 98: 602-609; 23341489
26. Neumann T, Lodes S, Kastner B, et al. Trabecular bone score in type 1 diabetes-a cross-sectional study. Osteoporos Int 2016; 27: 127-133; 26187124
27. Eller-Vainicher C, Filopanti M, Palmieri S, et al. Bone quality, as measured by trabecular bone score, in patients with primary hyperparathyroidism. Eur J Endocrinol 2013; 169: 155-162; 23682095
28. Leslie WD, Aubry-Rozier B, Lix LM, et al. Spine bone texture assessed by trabecular bone score (TBS) predicts osteoporotic fractures in men: The Manitoba Bone Density Program. Bone 2014; 67: 10-14; 24998455
29. Leslie WD, Johansson H, Kanis JA, et al. Lumbar spine texture enhances 10-year fracture probability assessment. Osteoporos Int 2014; 25: 2271-2277; 24951032
30. McCloskey EV, Oden A, Harvey NC, et al. A meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX. J Bone Miner Res 2015; doi: 10.1002/jbmr.2734. [Epub ahead of print
31. McCloskey EV, Oden A, Harvey NC, et al. Adjusting fracture probability by trabecular bone score. Calcif Tissue Int 2015; 96: 500-509
32. Leslie WD, Lix LM, Morin SN, et al. Hip axis length is a FRAX-and bone density-independent risk factor for hip fracture in women. J Clin Endocrinol Metab 2015; 100: 2063-2070; 25751108
33. Masud T, Morris RO. Epidemiology of falls. Age Ageing 2001; (30 Suppl 4): 3-7; 11769786
34. Dargent-Molina P, Favier F, Grandjean H, et al. Fall-related factors and risk of hip fracture: the EPIDOS prospective study. Lancet 1996; 348: 145-149; 8684153
35. Gardsell P, Johnell O, Nilsson BE, Nilsson JA. The predictive value of fracture, disease, and falling tendency for fragility fractures in women. Calcif Tissue Int 1989; 45: 327-330; 2509022
36. Harvey NC, Johansson H, Oden A, et al. FRAX predicts incident falls in elderly men: findings from MrOs Sweden. Osteoporos Int 2016; 27: 267-274; 26391036
37. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344: 333-340; 11172164
38. Kayan K, Johansson H, Oden A, et al. Can fall risk be incorporated into fracture risk assessment algorithms: a pilot study of responsiveness to clodronate. Osteoporos Int 2009; 20: 2055-2061
39. Masud T, Binkley N, Boonen S, Hannan MT. Official Positions for FRAX(R) clinical regarding falls and frailty: can falls and frailty be used in FRAX(R)? From Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(R). J Clin Densitom 2011; 14: 194-204; 21810525
40. Edwards MH, Jameson K, Denison H, et al. Clinical risk factors, bone density and fall history in the prediction of incident fracture among men and women. Bone 2013; 52: 541-547; 23159464
41. Giangregorio LM, Leslie WD, Lix LM, et al. FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res 2012; 27: 301-308; 22052532
42. Leslie WD, Morin SN, Lix LM, Majumdar SR. Does diabetes modify the effect of FRAX risk factors for predicting major osteoporotic and hip fracture? Osteoporos Int 2014; 25: 2817-2824
43. Schwartz AV, Vittinghoff E, Bauer DC, et al. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA 2011; 305: 2184-2192; 21632482
44. Cummings SR, Cosman F, Eastell R, et al. Goal-directed treatment of osteoporosis. J Bone Miner Res 2013; 28: 433-438; 23300146
45. Lewiecki EM, Cummings SR, Cosman F. Treat-to-target for osteoporosis: is now the time? J Clin Endocrinol Metab 2013; 98: 946-953; 23337726
46. McCloskey E, Leslie WD. Goal-directed therapy in osteoporosis. J Bone Miner Res 2013; 28: 439-441; 23300155
47. Kanis JA, McCloskey E, Branco J, et al. Goal-directed treatment of osteoporosis in Europe. Osteoporos Int 2014; 25: 2533-2543; 25199574
48. Leslie WD, Majumdar SR, Lix LM, et al. Can change in FRAX score be used to ?treat to target? A population-based cohort study. J Bone Miner Res 2014; 29: 1074-1080; 24877235
49. Committee for Medicinal Products for Human Use (CHMP) (2006) Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. CHMP, London, p Ref CPMP/EWP/552/595Rev.552
50. Kanis JA, Johansson H, Oden A, McCloskey EV. A meta-analysis of the effect of strontium ranelate on the risk of vertebral and nonvertebral fracture in postmenopausal osteoporosis and the interaction with FRAX((R)). Osteoporos Int 2011; 22: 2347-2355; 21287148
51. Harvey NC, Kanis JA, Oden A, et al. FRAX and the effect of teriparatide on vertebral and nonvertebral fracture. Osteoporos Int 2015; 26: 2677-2684; 26092063
52. Harvey NC, Kanis JA, Oden A, et al. Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX. Osteoporos Int 2015; 26: 2347-2353; 26092062
53. Kanis JA, Johansson H, Oden A, McCloskey EV. A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. Bone 2010; 47: 729-735; 20601292
54. McCloskey EV, Johansson H, Oden A, et al. Ten-year fracture probability identifies women who will benefit from clodronate therapy-dditional results from a double-blind, placebo-controlled randomised study. Osteoporos Int 2009; 20: 811-817; 19002369
55. Kanis JA, Johansson H, Oden A, McCloskey EV. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 2009; 44: 1049-1054; 19254788
56. McCloskey EV, Johansson H, Oden A, et al. Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res 2012; 27: 1480-1486; 22431426
57. Johansson H, Oden A, Johnell O, et al. Optimization of BMD measurements to identify high risk groups for treatment: a test analysis. J Bone Miner Res 2004; 19: 906-913; 15190881
58. Jarvinen TL, Michaelsson K, Jokihaara J, et al. Overdiagnosis of bone fragility in the quest to prevent hip fracture. BMJ 2015; 350: h2088; 26013536
59. Jarvinen TL, Sievanen H, Khan KM, et al. Shifting the focus in fracture prevention from osteoporosis to falls. BMJ 2008; 336: 124-126; 18202065
60. Scottish Intercollegiate Guidelines Network (SIGN) Management of osteoporosis and the prevention of fragility fractures. Edinburgh: SIGN; 2015. (SIGN publication no 142) [March 2015] Available from URL: http://wwwsignacuk. Accessed 25th Feb 2016
61. McCloskey E. A BMD threshold for treatment efficacy in osteoporosis? A need to consider the whole evidence base. Osteoporos Int 2016; 27: 417-419; 26564227
62. Ensrud KE, Black DM, Palermo L, et al. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch Intern Med 1997; 157: 2617-2624; 9531231
63. Roux C, Reginster JY, Fechtenbaum J, et al. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res 2006; 21: 536-542; 16598373
64. Kanis JA, Barton IP, Johnell O. Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture. Osteoporos Int 2005; 16: 475-482; 15875093
65. McCloskey E, Selby P, Davies M, et al. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. J Bone Miner Res 2004; 19: 728-736; 15068495
66. Eastell R, Black DM, Boonen S, et al. Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density. J Clin Endocrinol Metab 2009; 94: 3215-3225; 19567517
67. McClung M, Boonen S, Torring O, et al. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res 2012; 1: 211-218
68. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280: 2077-2082; 9875874
69. McCloskey EV, Beneton M, Charlesworth D, et al. Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J Bone Miner Res 2007; 22: 135-141; 17042717
70. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003; 290: 1729-1738; 14519707